S K Nadar1, A Blann, D G Beevers, G Y H Lip. 1. Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Abstract
BACKGROUND: The increased risk of target organ damage (TOD) in hypertension may be related to a prothrombotic or hypercoagulable state, with abnormalities in platelet activation. Altered angiogenesis, possibly related to increased plasma vascular endothelial growth factor (VEGF) is also a feature of hypertension. We hypothesized a link between altered angiogenesis and TOD in hypertension. Accordingly, the angiogenic growth factors VEGF, angiopoietin 1 and 2 (Ang 1 & 2) and soluble angiopoietin receptor Tie-2 in plasma and in platelets were assessed in terms of the presence or absence of hypertensive TOD. METHODS: We studied 199 patients (75% men; mean age 68 years) with hypertension. Of these, 125 had evidence of hypertensive TOD (stroke, previous myocardial infarction, angina, left ventricular hypertrophy and mild renal failure). Patients were compared with 74 healthy normotensive controls (69% men; mean age 68 years). Plasma VEGF, Ang 1 & 2 and Tie-2, and total platelet levels of VEGF and Ang-1 (obtained by lysing a known number of platelets with 0.5% Tween) were measured by an enzyme-linked immunosorbent assay. RESULTS: Hypertensive patients had higher levels of plasma VEGF, Ang-1, Ang-2, Tie-2 and platelet VEGF (all P<or=0.01), but not platelet Ang-1, when compared with normotensive controls. Patients with TOD had higher levels of platelet VEGF and Ang-1 (both P<0.001), and plasma Ang-1 (P<0.001). Amongst the hypertensives, plasma levels of VEGF correlated significantly with Ang-1, Ang-2, Tie-2 and platelet VEGF, whilst platelet VEGF correlated strongly with plasma levels of VEGF and Ang-1 (all P<0.05). CONCLUSION: Patients with hypertension have evidence of changes in plasma angiogenic growth factors that correlate with the platelet levels of these molecules. Platelets may be involved in the abnormal angiogenesis seen in hypertension.
BACKGROUND: The increased risk of target organ damage (TOD) in hypertension may be related to a prothrombotic or hypercoagulable state, with abnormalities in platelet activation. Altered angiogenesis, possibly related to increased plasma vascular endothelial growth factor (VEGF) is also a feature of hypertension. We hypothesized a link between altered angiogenesis and TOD in hypertension. Accordingly, the angiogenic growth factors VEGF, angiopoietin 1 and 2 (Ang 1 & 2) and soluble angiopoietin receptor Tie-2 in plasma and in platelets were assessed in terms of the presence or absence of hypertensive TOD. METHODS: We studied 199 patients (75% men; mean age 68 years) with hypertension. Of these, 125 had evidence of hypertensive TOD (stroke, previous myocardial infarction, angina, left ventricular hypertrophy and mild renal failure). Patients were compared with 74 healthy normotensive controls (69% men; mean age 68 years). Plasma VEGF, Ang 1 & 2 and Tie-2, and total platelet levels of VEGF and Ang-1 (obtained by lysing a known number of platelets with 0.5% Tween) were measured by an enzyme-linked immunosorbent assay. RESULTS:Hypertensivepatients had higher levels of plasma VEGF, Ang-1, Ang-2, Tie-2 and platelet VEGF (all P<or=0.01), but not platelet Ang-1, when compared with normotensive controls. Patients with TOD had higher levels of platelet VEGF and Ang-1 (both P<0.001), and plasma Ang-1 (P<0.001). Amongst the hypertensives, plasma levels of VEGF correlated significantly with Ang-1, Ang-2, Tie-2 and platelet VEGF, whilst platelet VEGF correlated strongly with plasma levels of VEGF and Ang-1 (all P<0.05). CONCLUSION:Patients with hypertension have evidence of changes in plasma angiogenic growth factors that correlate with the platelet levels of these molecules. Platelets may be involved in the abnormal angiogenesis seen in hypertension.
Authors: Ann M Stowe; Erik J Plautz; Ines Eisner-Janowicz; Shawn B Frost; Scott Barbay; Elena V Zoubina; Numa Dancause; Michael D Taylor; Randolph J Nudo Journal: J Cereb Blood Flow Metab Date: 2006-04-26 Impact factor: 6.200
Authors: Wolfgang Lieb; Justin P Zachariah; Vanessa Xanthakis; Radwan Safa; Ming-Huei Chen; Lisa M Sullivan; Martin G Larson; Holly M Smith; Qiong Yang; Gary F Mitchell; Joseph A Vita; Douglas B Sawyer; Ramachandran S Vasan Journal: Circ Cardiovasc Genet Date: 2010-03-26
Authors: Justin P Zachariah; Vanessa Xanthakis; Martin G Larson; Joseph A Vita; Lisa M Sullivan; Holly M Smith; Radwan Safa; Xuyang Peng; Naomi Hamburg; Daniel Levy; Douglas B Sawyer; Gary F Mitchell; Ramachandran S Vasan Journal: Hypertension Date: 2012-02-27 Impact factor: 10.190
Authors: H M C Shantha Kumara; Michael J Grieco; Xiaohong Yan; Matthew F Kalady; Vincent DiMaggio; Donald G Kim; Neil Hyman; Daniel L Feingold; Richard L Whelan Journal: Surg Endosc Date: 2010-03-31 Impact factor: 4.584
Authors: Berenice Y Reed; Amirali Masoumi; Elwaleed Elhassan; Kim McFann; Melissa A Cadnapaphornchai; David M Maahs; Janet K Snell-Bergeon; Robert W Schrier Journal: Kidney Int Date: 2010-09-29 Impact factor: 10.612
Authors: Clarence M Findley; Robert G Mitchell; Brian D Duscha; Brian H Annex; Christopher D Kontos Journal: J Am Coll Cardiol Date: 2008-07-29 Impact factor: 24.094
Authors: Julia C F Quintanilha; Yingmiao Liu; Amy S Etheridge; Akram Yazdani; Hedy L Kindler; William Kevin Kelly; Andrew B Nixon; Federico Innocenti Journal: Angiogenesis Date: 2021-05-24 Impact factor: 9.596